For the quarter ending 2026-03-31, CRNX made $10,734K in revenue. -$130,964K in net income. Net profit margin of -1220.09%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 10,734 | 6,161 | 143 | 1,031 |
| Cost of product revenue | 200 | 269* | - | - |
| Research and development | 100,081 | 85,053 | 90,464 | 80,301 |
| Selling, general and administrative | 50,831 | 54,505* | 52,265 | 49,842 |
| Total operating expenses | 151,112 | 139,827 | 142,729 | 130,143 |
| Loss from operations | -140,378 | -133,666 | -142,586 | -129,112 |
| Interest income | 12,664 | 11,156 | 12,544 | 13,455 |
| Other income (expense), net | - | - | - | 20 |
| Other expense, net | -131 | -125 | -49 | - |
| Total other income, net | 12,533 | 11,031 | 12,495 | 13,475 |
| Loss before income taxes | - | -122,770* | -130,091 | - |
| Income tax expense | - | 45* | - | - |
| Loss before equity method investment | - | -122,815* | - | 115,637 |
| Loss on equity method investment | - | 0* | 0 | 0 |
| Net loss | -127,845 | -122,815 | -130,091 | -115,637 |
| Unrealized loss (gain) on investment securities | -3,147 | -206 | 594 | -347 |
| Unrealized gain on foreign currency | 28 | -123 | -21 | -34 |
| Total other comprehensive income (gain) | -3,119 | -329 | 573 | -381 |
| Comprehensive loss | -130,964 | -123,144 | -129,518 | -116,018 |
| Basic EPS | -1.23 | -1.295 | -1.38 | -1.23 |
| Diluted EPS | -1.23 | -1.295 | -1.38 | -1.23 |
| Basic Average Shares | 104,099,000 | 95,120,000 | 94,215,000 | 93,791,000 |
| Diluted Average Shares | 104,099,000 | 95,120,000 | 94,215,000 | 93,791,000 |
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)